Chertow GM - Search Results

1

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

EVOLVE Trial Investigators; Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS. EVOLVE Trial Investigators, et al. Among authors: chertow gm. N Engl J Med. 2012 Dec 27;367(26):2482-94. doi: 10.1056/NEJMoa1205624. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121374 Free article. Clinical Trial.

2

The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients.

Chertow GM, Raggi P, McCarthy JT, Schulman G, Silberzweig J, Kuhlik A, Goodman WG, Boulay A, Burke SK, Toto RD. Chertow GM, et al. Am J Nephrol. 2003 Sep-Oct;23(5):307-14. doi: 10.1159/000072822. Epub 2003 Aug 12. Am J Nephrol. 2003. PMID: 12915774 Free article. Clinical Trial.

3

Determinants of progressive vascular calcification in haemodialysis patients.

Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Chertow GM, et al. Nephrol Dial Transplant. 2004 Jun;19(6):1489-96. doi: 10.1093/ndt/gfh125. Epub 2004 Apr 21. Nephrol Dial Transplant. 2004. PMID: 15102961

4

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Block GA, et al. Among authors: chertow gm. J Am Soc Nephrol. 2004 Aug;15(8):2208-18. doi: 10.1097/01.ASN.0000133041.27682.A2. J Am Soc Nephrol. 2004. PMID: 15284307

5

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Go AS, et al. Among authors: chertow gm. N Engl J Med. 2004 Sep 23;351(13):1296-305. doi: 10.1056/NEJMoa041031. N Engl J Med. 2004. PMID: 15385656 Free article.

6

Calcification or classification?

Chertow GM, Moe SM. Chertow GM, et al. J Am Soc Nephrol. 2005 Feb;16(2):293-5. doi: 10.1681/ASN.2004121115. Epub 2005 Jan 12. J Am Soc Nephrol. 2005. PMID: 15647332 No abstract available.

7

Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.

Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drüeke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ. Moe SM, et al. Among authors: chertow gm. Kidney Int. 2005 Feb;67(2):760-71. doi: 10.1111/j.1523-1755.2005.67139.x. Kidney Int. 2005. PMID: 15673327 Free article. Clinical Trial.

8

Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.

Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM. Raggi P, et al. Among authors: chertow gm. J Bone Miner Res. 2005 May;20(5):764-72. doi: 10.1359/JBMR.041221. Epub 2004 Dec 20. J Bone Miner Res. 2005. PMID: 15824849 Free article. Clinical Trial.

9

Beyond Framingham: cardiovascular risk profiling in ESRD.

McClellan WM, Chertow GM. McClellan WM, et al. Among authors: chertow gm. J Am Soc Nephrol. 2005 Jun;16(6):1539-41. doi: 10.1681/ASN.2005040415. Epub 2005 May 4. J Am Soc Nephrol. 2005. PMID: 15872082 No abstract available.

10

Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.

Chertow GM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM, Reed J; CONTROL Investigators. Chertow GM, et al. Clin J Am Soc Nephrol. 2006 Mar;1(2):305-12. doi: 10.2215/CJN.00870805. Epub 2006 Jan 25. Clin J Am Soc Nephrol. 2006. PMID: 17699221 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

815 results

Search Page